Vertex Telaprevir Nearing Phase III With Final Installment Of PROVE Program
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Vertex expects to complete enrollment in PROVE 3, its Phase IIb trial of the protease inhibitor telaprevir (VX-950), by the end of the second quarter and initiate Phase III trials of the hepatitis C agent in the second half of the year, Executive VP-Medicines Development John Alam told analysts during a Feb. 1 year-end earnings call.
You may also be interested in...
Vertex Phase IIb Data On Telaprevir Support 24-Week Dosing For Hepatitis C
Vertex released positive interim data from Phase IIb studies of its experimental protease inhibitor telaprevir for the treatment of hepatitis C Nov. 2 at the American Association of the Study of Liver Diseases meeting in Boston
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.